Prime Medicine, Inc.
PRME
$0.10
Change (1 day)
$9.86
Year High
$3.28
Year Low
Categories
Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Earnings for Prime Medicine, Inc. (PRME)
Earnings in 2023 (TTM): $-198,412,000
According to Prime Medicine, Inc.'s latest financial reports the company's current earnings (TTM) are $-198,412,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Prime Medicine, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-198,412,000 | $-198,133,000 |
| 2022 | $-122,769,000 | $-121,821,000 |
| 2021 | $-165,853,000 | $-165,367,000 |
| 2020 | $-1,543,000 | $-3,410,000 |
| 2019 | $-2,525,000 | $-2,529,000 |